Intellectus Partners LLC Raises Stake in Pfizer Inc. (NYSE:PFE)

Intellectus Partners LLC increased its stake in Pfizer Inc. (NYSE:PFE) by 11.1% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 83,435 shares of the biopharmaceutical company’s stock after buying an additional 8,352 shares during the quarter. Intellectus Partners LLC’s holdings in Pfizer were worth $2,402,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Investment Advisory Services Inc. TX ADV lifted its holdings in Pfizer by 1.6% during the third quarter. Investment Advisory Services Inc. TX ADV now owns 20,097 shares of the biopharmaceutical company’s stock valued at $667,000 after purchasing an additional 325 shares during the last quarter. Trifecta Capital Advisors LLC lifted its holdings in Pfizer by 3.7% during the third quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock valued at $305,000 after purchasing an additional 325 shares during the last quarter. Confluence Wealth Services Inc. lifted its holdings in Pfizer by 0.5% during the third quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock valued at $2,158,000 after purchasing an additional 342 shares during the last quarter. Carr Financial Group Corp lifted its holdings in Pfizer by 3.3% during the third quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock valued at $344,000 after purchasing an additional 355 shares during the last quarter. Finally, Caldwell Sutter Capital Inc. lifted its holdings in Pfizer by 0.5% during the third quarter. Caldwell Sutter Capital Inc. now owns 69,794 shares of the biopharmaceutical company’s stock valued at $2,315,000 after purchasing an additional 364 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on PFE. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Guggenheim began coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Eleven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $36.33.

Pfizer Price Performance

PFE traded up $0.14 on Friday, reaching $25.40. The company had a trading volume of 46,526,457 shares, compared to its average volume of 34,120,812. The business has a 50 day simple moving average of $26.96 and a 200 day simple moving average of $28.39. The company has a market cap of $143.83 billion, a price-to-earnings ratio of 70.56, a P/E/G ratio of 1.14 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.37.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business’s revenue was down 41.3% compared to the same quarter last year. During the same period last year, the firm posted $1.14 earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.61%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.